BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25416804)

  • 1. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.
    Tan Y; Watkins AA; Freeman BB; Meyers JA; Rifkin IR; Lerner A
    J Immunol; 2015 Jan; 194(1):101-12. PubMed ID: 25416804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
    Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
    Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
    Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
    Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
    Meyers JA; Taverna J; Chaves J; Makkinje A; Lerner A
    Clin Cancer Res; 2007 Aug; 13(16):4920-7. PubMed ID: 17699872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis.
    Tiwari S; Felekkis K; Moon EY; Flies A; Sherr DH; Lerner A
    Blood; 2004 Apr; 103(7):2661-7. PubMed ID: 14615375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.
    Moon EY; Lerner A
    Blood; 2003 May; 101(10):4122-30. PubMed ID: 12531792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine.
    Wolska A; Cebula-Obrzut B; Smolewski P; Robak T
    Leuk Lymphoma; 2013 Jun; 54(6):1268-78. PubMed ID: 23078646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia.
    Kim DH; Lerner A
    Blood; 1998 Oct; 92(7):2484-94. PubMed ID: 9746789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase-4 inhibition improves corticosteroid insensitivity in pulmonary endothelial cells under oxidative stress.
    Ortiz JL; Milara J; Lluch J; De Diego A; Sanz C; Cortijo J
    Allergy; 2013 Jan; 68(1):64-73. PubMed ID: 23121078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.
    Mongini PK; Gupta R; Boyle E; Nieto J; Lee H; Stein J; Bandovic J; Stankovic T; Barrientos J; Kolitz JE; Allen SL; Rai K; Chu CC; Chiorazzi N
    J Immunol; 2015 Aug; 195(3):901-23. PubMed ID: 26136429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous functional effects of concomitant B cell receptor and TLR stimulation in chronic lymphocytic leukemia with mutated versus unmutated Ig genes.
    Chatzouli M; Ntoufa S; Papakonstantinou N; Chartomatsidou E; Anagnostopoulos A; Kollia P; Ghia P; Muzio M; Stamatopoulos K; Belessi C
    J Immunol; 2014 May; 192(10):4518-24. PubMed ID: 24719462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors.
    Meyers JA; Su DW; Lerner A
    J Immunol; 2009 May; 182(9):5400-11. PubMed ID: 19380787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical assessment of curcumin as a potential therapy for B-CLL.
    Everett PC; Meyers JA; Makkinje A; Rabbi M; Lerner A
    Am J Hematol; 2007 Jan; 82(1):23-30. PubMed ID: 16947318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation.
    Ringelstein-Harlev S; Avivi I; Fanadka M; Horowitz NA; Katz T
    Cancer Immunol Immunother; 2018 May; 67(5):739-748. PubMed ID: 29450641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis.
    Foey AD; Field S; Ahmed S; Jain A; Feldmann M; Brennan FM; Williams R
    Arthritis Res Ther; 2003; 5(6):R317-28. PubMed ID: 14680506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
    Lehrke M; Kahles F; Makowska A; Tilstam PV; Diebold S; Marx J; Stöhr R; Hess K; Endorf EB; Bruemmer D; Marx N; Findeisen HM
    J Mol Cell Cardiol; 2015 Apr; 81():23-33. PubMed ID: 25640159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia.
    Zhang L; Murray F; Zahno A; Kanter JR; Chou D; Suda R; Fenlon M; Rassenti L; Cottam H; Kipps TJ; Insel PA
    Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19532-7. PubMed ID: 19033455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-kappaB activation.
    Hammadi A; Billard C; Faussat AM; Kolb JP
    Nitric Oxide; 2008 Sep; 19(2):138-45. PubMed ID: 18474259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PDE4 inhibitor rolipram prevents NF-kappaB binding activity and proinflammatory cytokine release in human chorionic cells.
    Hervé R; Schmitz T; Evain-Brion D; Cabrol D; Leroy MJ; Méhats C
    J Immunol; 2008 Aug; 181(3):2196-202. PubMed ID: 18641359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.